Melander SA - Search Results

1

OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes.

Melander SA, Kayed A, Andreassen KV, Karsdal MA, Henriksen K. Melander SA, et al. Eur J Pharmacol. 2024 Jan 5;962:176215. doi: 10.1016/j.ejphar.2023.176215. Epub 2023 Dec 5. Eur J Pharmacol. 2024. PMID: 38056618

2

Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin.

Melander SA, Katri A, Karsdal MA, Henriksen K. Melander SA, et al. Eur J Pharmacol. 2023 Jan 5;938:175397. doi: 10.1016/j.ejphar.2022.175397. Epub 2022 Nov 19. Eur J Pharmacol. 2023. PMID: 36414113

3

The Effects of Dual GLP-1/Glucagon Receptor Agonists with Different Receptor Selectivity in Mouse Models of Obesity and Nonalcoholic Steatohepatitis.

Kayed A, Melander SA, Khan S, Andreassen KV, Karsdal MA, Henriksen K. Kayed A, et al. Among authors: melander sa. J Pharmacol Exp Ther. 2023 Mar;384(3):406-416. doi: 10.1124/jpet.122.001440. Epub 2022 Nov 23. J Pharmacol Exp Ther. 2023. PMID: 36418115

4

Dual amylin and calcitonin receptor agonist treatment improves insulin sensitivity and increases muscle-specific glucose uptake independent of weight loss.

Larsen AT, Melander SA, Sonne N, Bredtoft E, Al-Rubai M, Karsdal MA, Henriksen K. Larsen AT, et al. Among authors: melander sa. Biomed Pharmacother. 2023 Aug;164:114969. doi: 10.1016/j.biopha.2023.114969. Epub 2023 Jun 1. Biomed Pharmacother. 2023. PMID: 37269811 Free article.

5

Dual amylin and calcitonin receptor agonist treatment reduces biomarkers associated with kidney fibrosis in diabetic rats.

Melander SA, Møller AL, Mohamed KE, Rasmussen DGK, Genovese F, Karsdal MA, Henriksen K, Larsen AT. Melander SA, et al. Am J Physiol Endocrinol Metab. 2023 Nov 1;325(5):E529-E539. doi: 10.1152/ajpendo.00245.2023. Epub 2023 Oct 4. Am J Physiol Endocrinol Metab. 2023. PMID: 37792041 Free article.

6

Are insulin sensitizers the new strategy to treat Type 1 diabetes? A long-acting dual amylin and calcitonin receptor agonist improves insulin-mediated glycaemic control and controls body weight.

Melander SA, Larsen AT, Karsdal MA, Henriksen K. Melander SA, et al. Br J Pharmacol. 2024 Jun;181(12):1829-1842. doi: 10.1111/bph.16329. Epub 2024 Feb 20. Br J Pharmacol. 2024. PMID: 38378168

7

The enduring metabolic improvement of combining dual amylin and calcitonin receptor agonist and semaglutide treatments in a rat model of obesity and diabetes.

Larsen AT, Mohamed KE, Melander SA, Karsdal MA, Henriksen K. Larsen AT, et al. Among authors: melander sa. Am J Physiol Endocrinol Metab. 2024 Aug 1;327(2):E145-E154. doi: 10.1152/ajpendo.00092.2024. Epub 2024 Jun 12. Am J Physiol Endocrinol Metab. 2024. PMID: 38864815

8

DACRA induces profound weight loss, satiety control, and increased mitochondrial respiratory capacity in adipose tissue.

Petersen EA, Blom I, Melander SA, Al-Rubai M, Vidotto M, Dalgaard LT, Karsdal MA, Henriksen K, Larsen S, Larsen AT. Petersen EA, et al. Among authors: melander sa. Int J Obes (Lond). 2024 Oct;48(10):1421-1429. doi: 10.1038/s41366-024-01564-w. Epub 2024 Jun 15. Int J Obes (Lond). 2024. PMID: 38879729

9

The dual amylin and calcitonin receptor agonist KBP-336 elicits a unique combination of weight loss, antinociception and bone protection - a novel disease-modifying osteoarthritis drug.

Mohamed KE, Larsen AT, Melander S, Andersen F, Kerrn EB, Karsdal MA, Henriksen K. Mohamed KE, et al. Arthritis Res Ther. 2024 Jul 12;26(1):129. doi: 10.1186/s13075-024-03361-2. Arthritis Res Ther. 2024. PMID: 38997785 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters